Novanta
🇺🇸 NASDAQ:NOVT
•
Dec 31, 2024
Novanta Q4 2024 Earnings Report
Novanta reported solid revenue and earnings growth in Q4 2024.
Key Takeaways
Novanta posted strong Q4 2024 results with revenue increasing by 12.5% year-over-year to $238.1 million. Net income rose to $16.5 million, and adjusted EPS grew 21% to $0.76. Operating cash flow saw a significant increase of 58%, indicating strong financial performance.
Revenue increased by 12.5% year-over-year to $238.1 million.
Net income rose 32% to $16.5 million.
Adjusted EPS increased 21% to $0.76.
Operating cash flow surged 58% to $61.6 million.
Novanta Revenue
Novanta EPS
Novanta Revenue by Segment
Forward Guidance
Novanta expects revenue growth in 2025, driven by new product launches in the medical sector, but remains cautious on capital spending trends in industrial and semiconductor markets.
Positive Outlook
- Projected $1 billion in revenue for FY 2025.
- Expected Adjusted EBITDA between $225M-$235M.
- Incremental $50M in new product sales, mainly in medical technology.
- Medical segment expected to show continued strength.
- Optimism on slow recovery in industrial and semiconductor markets.
Challenges Ahead
- Volatile capital spending in industrial and semiconductor markets.
- Trade war uncertainty affecting business outlook.
- Geopolitical risks may impact market recovery.
- Foreign exchange fluctuations could affect revenue.
- Guidance remains conservative until recovery trends are confirmed.
Revenue & Expenses
Visualization of income flow from segment revenue to net income